gemcitabine has been researched along with cyclin d1 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, CP; Motwani, MV; Schwartz, GK | 1 |
| Balasubramanian, S; Chandraratna, RA; Eckert, RL | 1 |
| Banerjee, S; Biliran, H; Bollig, A; Heng, H; Liao, JD; Sarkar, FH; Thakur, A; Wang, Y; Xu, H | 1 |
| Brunetti, E; Bucci, B; Michienzi, S; Misiti, S; Panacchia, L; Patriarca, V; Stigliano, A; Toscano, V; Verga Falzacappa, C | 1 |
| He, SM; Huang, YJ; Leng, TD; Li, Y; Ou, YQ; Qiu, PX; Xie, J; Xu, D; Yan, GM; Zheng, XK; Zhu, Wb | 1 |
| Bisht, S; Chenna, V; Feldmann, G; Goggins, MG; Hong, SM; Karikari, C; Maitra, A; Mizuma, M; Ottenhof, NA; Pramanik, D; Ravi, R; Rudek, MA; Sharma, R | 1 |
| Fukuda, S; Guo, Z; Kathuria, H; Milani, M; Mitra, R; Pelus, LM; Potter, DA; Rizzardi, A; Rodriguez, M; Schmechel, S; Skalnik, DG; Srirangam, A | 1 |
| Gou, S; Shi, P; Wang, C; Wei, H; Yang, Z; Yin, T; Zhao, G | 1 |
| Chang, S; Chung, YH; Hwang, Y; Kim, NY; Kim, S; Kim, SJ; Koh, SS; Lee, Y; Min, HJ; Park, EH; Park, YW; Yoo, KS | 1 |
| Chen, F; Hu, Y; Li, H; Liu, H; Tao, H; Wang, Y | 1 |
| Liang, J; Ma, Y; Tian, X; Wang, F; Xie, X; Yang, C; Yang, Y; Zhang, Z | 1 |
| Baek, YY; Fang, S; Jang, SI; Lee, DH; Lee, DK; Lee, SY; Na, K | 1 |
| Gao, LF; Han, J; Li, XL; Liu, QY; Liu, ZJ; Wang, XH; Xu, W | 1 |
| Bolidong, D; Domoto, T; Minamoto, T; Miyashita, T; Takenaka, S; Takeuchi, O; Uehara, M | 1 |
14 other study(ies) available for gemcitabine and cyclin d1
| Article | Year |
|---|---|
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cyclin D1; Cyclin E; Cysteine Endopeptidases; Cytochrome c Group; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; E2F Transcription Factors; E2F1 Transcription Factor; Enzyme Inhibitors; Flavonoids; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Mitochondria; Multienzyme Complexes; Phosphorylation; Piperidines; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Protein Subunits; Retinoblastoma Protein; Ribonucleotide Reductases; RNA, Messenger; Thymidine; Transcription Factors; Tritium; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Deoxycytidine; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interferon-gamma; Ligands; Pancreatic Neoplasms; Plasmids; Protein Binding; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Tetrahydronaphthalenes; Time Factors; Transcription Factors | 2004 |
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Culture Media; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Transgenic; NF-kappa B; Pancreatic Elastase; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2005 |
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Deoxycytidine; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; p21-Activated Kinases; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Thyroid Hormone; Triiodothyronine | 2007 |
Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Aspirin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2010 |
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Matrix Metalloproteinase 9; Mice; Nanoparticles; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Polymers; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2010 |
The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Cyclin D1; Deoxycytidine; DNA Breaks, Double-Stranded; Drug Therapy, Combination; Gemcitabine; HIV Protease Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2011 |
Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; CD24 Antigen; Cell Line; Cell Movement; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hyaluronan Receptors; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Polycomb Repressive Complex 1; Vimentin | 2011 |
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Cyclin D1; Deoxycytidine; Disease Progression; Endothelial Cells; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lectins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Proteins; Beclin-1; Bone Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Gemcitabine; Genes, bcl-2; Humans; Lysosomal Membrane Proteins; Osteosarcoma; Wnt Signaling Pathway | 2017 |
Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Growth Processes; Cell Line, Tumor; Cyclin A2; Cyclin D1; Deoxycytidine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Random Allocation; RNA, Messenger; Triterpenes; Xenograft Model Antitumor Assays | 2018 |
Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
Topics: Animals; Antigens, CD; Cadherins; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Cyclin B; Cyclin D1; Deoxycytidine; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-cbl; Signal Transduction; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2020 |
Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Suppressor Protein p53 | 2020 |
Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gemcitabine; Glycogen Synthase Kinase 3 beta; Heterografts; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Thymidine Kinase; Thymidylate Synthase; Transcription, Genetic | 2020 |